Close Menu
Technology Mag

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    This Smart Basketball Tracks Data About Every Shot. It Could Be Headed to the NBA

    July 31, 2025

    Oakley Meta HSTN Limited Edition review: a polarizing choice

    July 31, 2025

    DJI’s first 360-degree camera can continuously capture 8K footage for over 100 minutes

    July 31, 2025
    Facebook X (Twitter) Instagram
    Subscribe
    Technology Mag
    Facebook X (Twitter) Instagram YouTube
    • Home
    • News
    • Business
    • Games
    • Gear
    • Reviews
    • Science
    • Security
    • Trending
    • Press Release
    Technology Mag
    Home » 23andMe Is Under Fire. Its Founder Remains ‘Optimistic’
    Science

    23andMe Is Under Fire. Its Founder Remains ‘Optimistic’

    News RoomBy News RoomFebruary 14, 20243 Mins Read
    Facebook Twitter Pinterest LinkedIn Reddit WhatsApp Email

    You had an exclusive partnership with GlaxoSmithKline for five years, from 2018 to 2023. How successful was that?

    It was overwhelmingly productive. Fifty drug targets came out of it, far more than we expected. They upped it again for one more year, the sixth year, though it’s non-exclusive now. We now have the ability to mine the dataset for ourselves, as well as to partner with other groups. Both the 23andMe and the GSK team felt like there was so much in there, any one group can’t possibly mine everything. It’s a real resource that we could apply to a number of different organizations for their own drug discovery.

    Are there particular disease areas that you are really interested in?

    We’ve narrowed our own discovery efforts into inflammation immunology, and particularly on asthma. We are also focused on our immuno-oncology programs, but that’s more on the [drug] development side.

    Speaking of, you have a drug in a Phase 2 trial, an antibody for solid tumor cancers, and you just announced that you’re starting a Phase 1 trial for a second drug, known as a natural killer cell activator, also for cancer. Did you identify those drugs based on your genetic data?

    We did. It’s really exciting seeing genetic data transform into a hypothesis that goes into a drug and actually seeing the impact on patients.

    Do you think most 23andMe customers are aware that if they opt in to participating in research they’re also opting in to their data being used by potential pharma partners?

    It’s not individual level data, unless they explicitly consented for individual level data. I think that most people want to see improvements in their lives. 23andMe can take it so far. But then we’re going to need to partner with others to really accelerate in a number of different disease areas.

    How early on in the company’s history did you start thinking about drug development as a direction that 23andMe might go in?

    Drug discovery was always really interesting to me. I just love the space. I think it’s incredibly interesting to be able to understand genetics and then have that apply and help understand and elucidate biology. The original iterations were about us not doing as much ourselves but rather that we would partner it with other pharma companies.

    It has been a little more than 20 years now since the Human Genome Project was completed, yet the integration of genetics and genomics into medical care has not been fully realized. Why is that?

    The biggest question around genetics is about the cost. In the US health care system, because the employers are paying for most health care and the average time that employees are at a job is three years, then you kind of look at: What’s your three-year investment time horizon, and will it pay off in that timeframe? So, I think it’s a lot about, you know, when does preventative care pay off? I think one of the things that’s a little bit of a sad truth for individuals is that what’s necessarily best for the entire population is not necessarily what’s best for you.

    Share. Facebook Twitter Pinterest LinkedIn WhatsApp Reddit Email
    Previous ArticleStability AI tries to stay ahead of the pack with a new image-generating AI model
    Next Article The best Presidents Day deals you can already get

    Related Posts

    How Do You Live a Happier Life? Notice What Was There All Along

    July 30, 2025

    EPA Employees Still in the Dark as Agency Dismantles Scientific Research Office

    July 30, 2025

    This Star System Contains 5 Potentially Habitable Planets

    July 30, 2025

    The Hunt for a Fundamental Theory of Quantum Gravity

    July 29, 2025

    South Korea Plans to Build a Base on the Moon

    July 29, 2025

    The First Planned Migration of an Entire Country Is Underway

    July 29, 2025
    Our Picks

    Oakley Meta HSTN Limited Edition review: a polarizing choice

    July 31, 2025

    DJI’s first 360-degree camera can continuously capture 8K footage for over 100 minutes

    July 31, 2025

    How Apple’s New Spotlight Compares to Raycast

    July 31, 2025

    Uber Eats is adding AI to menus, food photos, and reviews

    July 31, 2025
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss
    News

    Hey Microsoft, is it “Xbox PC” or “Xbox on PC”?

    By News RoomJuly 31, 2025

    Microsoft first started using the “Xbox PC” term in a blog post announcing the Gears…

    15% Off Theragun Promo Code for August 2025

    July 31, 2025

    Meta is playing the AI game with house money

    July 30, 2025

    Ready or not, age verification is rolling out across the internet

    July 30, 2025
    Facebook X (Twitter) Instagram Pinterest
    • Privacy Policy
    • Terms of use
    • Advertise
    • Contact
    © 2025 Technology Mag. All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.